Lung Cancer
Watch Time: 6 mins

Prasad S Adusumilli, ELCS 2022: Potential of CAR-T Therapy in Lung Cancer

Published Online: May 5th 2022

There is still extensive ongoing research, however CAR-T technology for lung cancer is providing much promise but many challenges. touchONCOLOGY spoke to Dr Prasad S Adusumilli (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) to discuss the potential of CAR-T therapy in lung cancer and the recent breakthroughs in this area. 

Questions

  1.       What are the barriers to the use of CAR-T therapies in solid tumours, and how can these be overcome? 00:24-01:46
  2.       Could you tell us a little about the findings from your research on CAR T-cell therapy for mesothelioma? 01:46-03:24
  3.       What is the rationale for using immune checkpoint inhibitors in combination with CAR T-cell therapy? 03:24-04:35
  4.       What will be the next steps in your research? 04:35-05:34
  5.       What other molecular targets are currently under evaluation for CAR T-cell therapy for lung cancer? 05:34-

Speaker Disclosure: Prasad S Adusumilli is a consultant for: Atara Biotherapeutics, Bayer, Johnson&Johnson and Orion Pharma. He has received grant and research support from: Atara Biotherapeutics, Baker Street Foundation, Batishwa Fellowship, Comedy vs Cancer Award, DallePezze Foundation, Derfner Foundation, Esophageal Education Research Foundation (ECEF), DOD (BC132124, LC160212, CA170630, CA180889, CA200437), Experimental Therapeutics Center (MSK), Geoffrey Beene Foundation (MSK), NCI (R01 CA236615-01, R01 CA 235667-01A1, R01 CA217169-01A1, R21 CA213139, T32, P30 CA008748) and Technology Development Fund (MSK). He is a member of the advisory board for: BioArdis, Carisma Therapeutics, Bayer, Imugene and ImmPACT Bio. He is a major stock shareholder in: ImmPACT Bio. Other Financial or Material Support: Licensing and Royalty from Mesothelin CAR and PD1 DNR licensed to Atara Biotherapeutics; Patents (issued and applications): Mesothelin CAR, PD1DNR, CARs with new targets and costimulatory domain, Ex-vivo pleural effusion culture system (ePECS), Wireless pulse oximetry (Wipox) device and detection of cancer cells by oncolytic virus.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the European Lung Cancer Summit 2022

Share this Video
Related Videos In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72